Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy‐induced immunosuppression
暂无分享,去创建一个
A. Österborg | F. Mozaffari | J. Lundin | E. Rossmann | L. Hansson | A. Porwit | S. Norin | C. Karlsson | S. E. Sylvan